About the Company
Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions. The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SCPS News
Scopus BioPharma Inc. (SCPS)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Scopus (SCPS) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Sunshine Biopharma Inc SBFM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
FWBI First Wave BioPharma, Inc.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with ...
UK biopharma company IntraBio moves HQ to Austin, raises $40M
A U.K.-based biopharmaceutical company that just raised a new round of funding moved its corporate headquarters to Austin.
Sutro Biopharma Inc STRO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
LABP Landos Biopharma, Inc.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut ...
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock?
Investors might want to bet on First Wave BioPharma, Inc. (FWBI), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
AEON Biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery ...
Theravance Biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Scopus Biopharma Inc (SCPS)
After the activity, the stock price went up +44.85% to $0.3401. The overall... Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics ...
Loading the latest forecasts...